Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 10/20 | 0.69 |
| ▸ | IKBKB | O14920 | 3/20 | 0.50 |
| ▸ | CDC7 | O00311 | 2/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428574 | 0.86 | KMT2A (0.52) | RORBIKBKBCDC7DBF4KMT2A | |
| SCHEMBL257615 | 0.85 | RORB (0.72) | RORBALDH1A1CDK2 | |
| SCHEMBL257432 | 0.84 | RORB (0.74) | RORBALDH1A1HSD17B10CDK2 | |
| SCHEMBL10092885 | 0.84 | RORB (0.70) | RORB | |
| SCHEMBL2491634 | 0.82 | POLB (0.55) | RORBIKBKBCDC7DBF4KMT2A | |
| SCHEMBL257572 | 0.82 | RORB (1.00) | RORB | |
| SCHEMBL2521905 | 0.82 | ALDH1A1 (0.62) | RORBIKBKBCDC7DBF4KMT2A | |
| SCHEMBL2489842 | 0.81 | ALDH1A1 (0.73) | RORBCDC7DBF4KMT2AALDH1A1 | |
| SCHEMBL257436 | 0.81 | RORB (0.66) | RORBKMT2A | |
| SCHEMBL10092890 | 0.80 | RORB (0.65) | RORBCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102256972-A | Thiazolyl-benzimidazoles | HOFFMANN LA ROCHE | 2011-11-23 | — | — | CN | disclosed |
| EP-2379543-A2 | THIAZOLYL-BENZIMIDAZOLES | F. Hoffmann-La Roche AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010121675-A2 | THIAZOLYL-BENZIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | RORB 470/4885IKBKB 1034/4885CDC7 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.